 By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update FDA Approves Clinical Plan for MN-166 to Prevent ARDS Caused by COVID-19 On July 1, 2020, MediciNova, Inc. NASDAQ:MNOV announced that the companys Investigational New Drug application IND for MN-166 ibudilast for the prevention of acute respiratory distress syndrome ARDS caused by COVID-19 was approved by 